

10/073,334

SEQUENCE LISTING

C1107 Applicant: Steven J. Soldin
C1207 Title of invention: A Novel 8.4 kDa Immunophilin
C1307 File reference: 64688/155
C1407 Current application no.: TBA 10/073,334
C1417 Current filing date: TBA 2002-02-13
C1507 Prior application: 09/643,723
C1517 Prior application filing date: 08/30/2000 2003-08-30

Does Not Comply
Corrected Diskette Needed

C1607 Number of SEQ. ID. NOS.: 1
C1707 Software: ASCII (DOS) generic word processing

C2107 1

C2117 Length: 23

C2127 Type: Amino acid sequence PRT

C2137 Organism: mammal

C24007 SEQ. ID. NO. 1

MET GLN ILE PHE VAL LYS THR LEU THR GLY

1 5 10

LYS THR ILE THR LEU GLU VAL GLU PRO SER

15 20

ASP THR ILE

invalid- The initial letter of the
amino acid is in upper-case.
e.g., Met Gln

The above is the valid format for a Sequence
Listing. Please consult Sequence Rules and
the attached sample Sequence Listing for valid
format

<110> Smith, John; Smithgene Inc.

<120> Example of a Sequence Listing

<130> 01-00001

<140> PCT/EP98/00001
<141> 1998-12-31

<150> US 08/999,999
<151> 1997-10-15

<160>

<170> PatentIn version 2.0

<210> 1
<211> 389
<212> DNA
<213> Paramecium sp.

<220>
<221> CDS
<222> (279)...(389)

<300>
<301> Doc, Richard
<302> Isolation and Characterization of a Gene Encoding a
Protease from Paramecium sp.
<303> Journal of Genes
<304> 1
<305> 4
<306> 1-7
<307> 1988-06-31
<308> 123456
<309> 1988-06-31

<400> 1
agctcgatgc atatccgtgt ccttcctctt ctgggcctct cacccctgca atcagatctc 60
agggagatcg tcttgaccct cctctgcctt tgcagcttca caggcaggca ggcaggcagc 120
tgcgtggca atcgctggca gtgccacagg ctttcagcc aggttaggg tgggtttccgc 180
cgcggcgccgg cggccccctt cggcgctctt tcggcgctctt ctctcgctctt ccttcgctc 240

Appendix 3, page 2

ggacacctgatt aggtgagcag gaggagggggg cagttgcg atg gtc tca atg ttc agc 296
 Met Val Ser Met Phe Ser
 1 5 9 13 17 21

tgc tct ttc aaa tgg cct gga ttt tgt ttg ttt gtt tgt ttg ttc cca 344
 Leu Ser Phe Lys Trp Pro Gly Phe Cys Leu Phe Val Cys Leu Phe Cln
 10 14 18 22 26 30

tgt ccc aaa gtc ctc ccc tgt cac tca tca ctg cag ccg aat ctt 389
 Cys Pro Lys Val Leu Pro Cys His Ser Ser Leu Cln Pro Asn
 25 29 33 37

<210> 2
 <211> 37
 <212> PRT
 <213> Paramecium sp.

<<00> 2
 Met Val Ser Met Phe Ser Leu Ser Phe Lys Trp Pro Gly Phe Cys Leu
 1 5 9 13 17 21 25 29 33 37 41 45 49 53

Phe Val Cys Leu Phe Cln Cys Pro Lys Val Leu Pro Cys His Ser Ser
 20 24 28 32 36 40 44 48 52 56 60 64 68 72

Leu Cln Pro Asn Leu
 35 39

<210> 3
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Designed peptide based on size and polarity to act as a linker between the alpha and beta chains of Protein XYZ.

<400> 3
 Met Val Asn Leu Glu Pro Met His Thr Glu Ile
 1 5 9 13 17 21 25 29 33 37

<210> 4
 <400> 4
 000

[Annex VIII follows]

identifiers and their accompanying information as shown in the following table. The numeric identifier shall be used only in the "Sequence Listing." The order and presentation of the items of information in the "Sequence Listing" shall conform to the arrangement given below. Each item of information shall begin on a new line and shall begin with the numeric identifier enclosed in angle brackets as shown. The submission of those items of information designated with an "M" is mandatory. The submission of those items of information designated with an "O" is optional. Numeric identifiers <110> through <170> shall only be set forth at the beginning of the "Sequence Listing." The following table illustrates the numeric identifiers.

Numeric Identifier	Definition	Comments and Format	Mandatory (M) or Optional (O)
<110>	Applicant	Preferably max. of 10 names; one name per line; preferable format: Surname, Other Names and/or Initials	M
<120>	Title of Invention		M
<130>	File Reference	Personal file reference	M, when filed prior to assignment of appl. number
<140>	Current Application Number	Specify as: US 07/999,999 or PCT/US96/99999	M, if available
<141>	Current Filing Date	Specify as: yyyy-mm-dd	M, if available
<150>	Prior Application Number	Specify as: US 07/999,999 or PCT/US96/99999	M, if applicable include priority documents under 35 USC 119 and 120
<151>	Prior Application Filing Date	Specify as: yyyy-mm-dd	M, if applicable
<160>	Number of SEQ ID NOS	Count includes total number of SEQ ID NOS	M
<170>	Software	Name of software used to create the Sequence Listing	O
<210>	SEQ ID NO:#:	Response shall be an integer representing the SEQ ID NO shown	M
<211>	Length	Respond with an integer expressing the number of bases or amino acid residues	M

<212>	Type	Whether presented sequence molecule is DNA, RNA, or PRT (protein). If a nucleotide sequence contains both DNA and RNA fragments, the type shall be "DNA." In addition, the combined DNA/RNA molecule shall be further described in the <220> to <223> feature section.	M
<213>	Organism	Scientific name, i.e. Genus/species, Unknown or Artificial Sequence. In addition, the "Unknown" or "Artificial Sequence" organisms shall be further described in the <220> to <223> feature section.	M
<220>	Feature	Leave blank after <220>. <221-223> provide for a description of points of biological significance in the sequence.	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence; if ORGANISM is "Artificial Sequence" or "Unknown"; if molecule is combined DNA/RNA.
<221>	Name/Key	Provide appropriate identifier for feature, preferably from WIPO Standard ST.25 (1998), Appendix 2, Tables 5 and 6	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence
<222>	Location	Specify location within sequence; where appropriate state number of first and last bases/amino acids	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified

		" in feature as used in a s ence
<223>	Other Information	Other relevant information; four lines maximum
		M, under the following conditions: if "n," "Xaa," or a modified or un- usual L-amino acid or modified base was used in a sequence; if ORGANISM is "Artificial Sequence" or "Unknown"; if molecule is com- bined DNA/RNA
<300>	Publication Information	Leave blank after <300>
<301>	Authors	Preferably max of ten named authors of publi- cation; specify one name per line; preferable format: Surname, Other Names and/or Initials
<302>	Title	0
<303>	Journal	0
<304>	Volume	0
<305>	Issue	0
<306>	Pages	0
<307>	Date	Journal date on which data published; specify as yyyy-mm- dd, MM-yyyy or Season-yyyy
<308>	Database Accession Number	Accession number assigned by data- base including database name
<309>	Database Entry Date	Date of entry in database; specify as yyyy-mm-dd or MM-yyyy
<310>	Patent Document Number	Document number; for patent-type citations only. Specify as, for example, US 07/999,999

<311>	Patent Filing Date	Document filing date, for patent-type citations only; specify as yyyy-mm-dd	O
<312>	Publication Date	Document publication date, for patent-type citations only; specify as yyyy-mm-dd	O
<313>	Relevant Residues	FROM (position) TO (position)	O
<400>	Sequence	SEQ ID NO should follow the numeric identifier and should appear on the line preceding the actual sequence	IM

5. Section 1.024 is revised to read as follows:

1.024 Form and format for nucleotide and/or amino acid sequence submissions in computer readable form.

(a) The computer readable form required by 1.021(c) shall meet the following specifications:

- (1) The computer readable form shall contain a single "Sequence Listing" as either a diskette, series of diskettes, or other permissible media outlined in paragraph (c) of this section.
- (2) The "Sequence Listing" in paragraph (a) (1) of this section shall be submitted in American Standard Code for Information Interchange (ASCII) text. No other formats shall be allowed.
- (3) The computer readable form may be created by any means, such as word processors, nucleotide/amino acid sequence editors or other custom computer programs; however, it shall conform to all specifications detailed in this section.
- (4) File compression is acceptable when using diskette media, so long as the compressed file is in a self-extracting format that will decompress on one of the systems described in paragraph (b) of this section.
- (5) Page numbering shall not appear within the computer readable form version of the "Sequence Listing" file.

(6) All computer readable forms shall have a label permanently affixed thereto on which has been hand-printed or typed: the name of the applicant, the title of the invention, the date on which the data were recorded on the computer readable form, the operating system used, a reference number, and an application serial number and filing date, if known.

(b) Computer readable form submissions must meet these format requirements:

- (1) Computer: IBM PC/XT/AT, or compatibles, or Apple Macintosh;
- (2) Operating System: MS-DOS, Unix or Macintosh;